Coronavirus vaccine - Sanofi pasteur
Alternative Names: COVID-19Latest Information Update: 28 Mar 2024
At a glance
- Originator National Institute of Allergy and Infectious Diseases; sanofi pasteur
- Developer Biomedical Advanced Research and Development Authority; Sanofi Pasteur
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
- Discontinued Severe acute respiratory syndrome
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 24 Feb 2020 Sanofi Pasteur reinitiates the development of coronavirus vaccine in collaboration with Biomedical Advanced Research and Development Authority
- 18 Feb 2020 Sanofi Pasteur collaborates with Biomedical Advance Research and Development Authority (BARDA) from US Department of Health and Human Services for development of coronavirus vaccine